Wednesday, October 23, 2013

Immunovaccine Inc. - IMV.v

Immunovaccine Inc. - IMV.v is a clinical-stage vaccine development company focused on advancing its patented DepoVax™ vaccine adjuvanting platform and product candidates for cancer therapy, infectious disease and animal health.

The company has advanced its platform technology and proprietary cancer vaccines into Phase I human clinical trials and has demonstrated both safety and immunogenicity potential.

On September 9, 2013 the company released News

Immunovaccine Inc. (“Immunovaccine” or the "Company”) (TSX-V: IMV), a clinical stage vaccine company, today announced positive results from anthrax challenge studies in rabbits and non-human primates using its DepoVax™ delivery system. The studies showed that all animals administered a vaccine containing recombinant protective antigen (PA) formulated in DepoVax were protected against a lethal anthrax challenge.

Importantly, a single dose of DepoVax containing five micrograms of recombinant PA protected rabbits exposed to a lethal anthrax dose. Antibody titers plateaued in rabbits within 28 days highlighting the DepoVax platform’s potential to enable a single-dose, rapid response anthrax vaccine. These studies, conducted under the National Institute of Allergy and Infectious Diseases’ (NIAID’s) preclinical services program, were intended to evaluate Immunovaccine’s DepoVax adjuvanting technology and advance the development of next generation bio-defense vaccines.